WO1983000288A1 - A stable aqueous, therapeutic insulin preparation and a process for preparing it - Google Patents
A stable aqueous, therapeutic insulin preparation and a process for preparing it Download PDFInfo
- Publication number
- WO1983000288A1 WO1983000288A1 PCT/DK1982/000068 DK8200068W WO8300288A1 WO 1983000288 A1 WO1983000288 A1 WO 1983000288A1 DK 8200068 W DK8200068 W DK 8200068W WO 8300288 A1 WO8300288 A1 WO 8300288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- formula
- preparation
- compound
- medium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention relates to a novel stable therapeutic insulin preparation in an aqueous medium suitable for use in insulin delivery devices, including portable devices for external as well as internal use.
- insulin delivery devices which can remedy the above-mentioned problem. If, however, such devices are applied internally or externally to a human, insulin preparations experience far inferior storage conditions in terms of temperature and motion when stored in the reservoir of the device than the injectable preparations.
- the previously known insulin preparations are intended for storage at rest at 4oC.
- the insulin preparation is stored in the reservoir of insulin devices for an extended period of time at temperatures between 30 and 37oC. and is moreover subjected to a good deal of motion during this period.
- n 2 - 80, preferably 8-45
- Y represents oxygen or imino
- R 1 represents hydrogen, methyl or ethyl, where the groups
- R 1 may be the same or different, with the proviso that methyl or ethyl is present in at least half of the chain links X, and R 2 and R 3 independently represent hydrogen or an organic group, preferably alkyl of 1 to 20 carbon atoms, carboxyalkyl of 2 to 20 carbon atoms or alkylphenyl of 1 to 10 alkyl carbon atoms, with the proviso that when Y represents imino R 2 can only represent alkyl of 1 to 20 carbon atoms.
- These surfactants "saturate" the interfaces since the hydrophobic groups of the chains bind well to a larger hydrophobic face.
- the invention relates to a stable aqueous, therapeutic insulin preparation which is particularly useful in insulin delivery devices and is unique in that the aqueous medium has a pH of 6.5 to 9 and contains a polyoxyethylene alkylether of the general formula
- R represents a straight or branched, saturated or unsaturated C 8 - C 15 alkyl group, and n is an integer from 2 to 25.
- Preferred compounds are in particular those of formula 4 wherein R represents a C 12 - C 13 alkyl group, preferably lauryl or tridecyl, because they give the best stability.
- n in the compounds of formula 4 is an integer, preferably from 4 to 23, in particular 6 to 15.
- These polyoxyethylene alkylethers are active in insulin preparations in an aqueous medium in concentrations down to 2 ppm. The effect for concentrations between 2 and 100 ppm is demonstrated below, but the compounds are also active in higher concentrations, such as 100 to
- concentration most appropriate in the individual case can be determined by tests and depends e.g. upon the type of the compound, the concentration of insulin and the other components of the medium, as well as upon the mode of application of the preparation.
- the above-mentioned compounds are comprised by the general formula for a group of non-ionic surfactants which prevent denaturation of insulin and adsorption to interfaces according to the DE Offenlegun ⁇ sschrift 29 17 53.5.
- the compounds used in accordance with the invention are not described in detail or examined in the examples of that specification/ which are included in the EP 18609 claiming priority from this DE application.
- the formula of the active compounds is restricted to formula 1 above.
- Compounds of the type used in accordance with the invention have directly been characterized as having no protective effect during the processing of the EP 18609 by the EPO in connection with a discussion of the DE Auslegeschrift 26 20 483.
- the solutions have a pH of 2.5 to 4.7 and contain one or more non-ionic surfactants having an HLB value of 9 to 22 and/or polyethylene glycol having a molecular weight of 200 to 7500 as a stabilizer to counteract the ceamidation of the insulin, well-known in the acid pH range, and to improve the shelf-life by counteracting gel formation and precipitations.
- the content of surfactant usually constitutes 0.1 to 20% by weight, preferably 0.5 to 10% by weight. A content below 0.1% is characterized as being insufficient.
- R' and n have values corresponding to formula 4, are inactive as stabilizers in shaking tests.
- the Zn content in the medium can constitute 0 to 5%, preferably 0 to 1%, in particular 0.3 to 1% of the insulin, expressed as weight per cent of anhydrous insulin.
- a particularly good effect of the polyoxyethylene alkylethers is obtained when the Zn content in the dissolved insulin constitutes between 0.6 and 0.9%.
- the pH value is, as mentioned, between 6.5 and 9.0, but is preferably 6.5 to 8.0, in particular 7.0 to 8.0.
- the insulin concen tration may be up to 1500 IU/ml.
- aqueous insulin preparations for the use described can be prepared by the following general procedure:
- Human or animal insulin or biologically active derivatives thereof are dissolved in water with addition of e.g. an HCl solution.
- the Zn content is adjusted by adding a solution of a Zn salt in water.
- the resulting solution is admixed with a solution that may contain a preservative, such as phenol, m-cresol or p-methylhydroxy benzoate; an isotonic, such as glucose, glycerol or sodium chloride, and - to maintain a specific pH - a buffer such as acetate or sodium phosphate. pH is adjusted to the desired value e.g. with an NaOH solution or an HCl solution.
- the stabilizing polyoxyethylene alkylether dissolved in water is added.
- the insulin may be dissolved directly in an aqueous medium containing a buffer, an isotonic, a preservative and the stabilizing compound, and then the Zn content and the pH are adjusted.
- the order of these steps is arbitrary, it being possible to vary it in different ways; e.g. the stabilizing polymer might be added to the insulin during the purification process of the insulin.
- the invention also relates to a process for preparing the present insulin preparations which comprises admixing an aqueous medium containing insulin with a polyoxyethylene alkylether of the formula
- Crystalline pork insulin corresponding to 100,000 IU containing 0.4% Zn was dissolved in 400 ml of water by means of 3.3 ml of IN HCl. 10 ml of a ZnCl 2 solution were added, containing 2.20 mg of ZnCl 2 per ml. Then were added 500 ml of a solution of 3.0 g of m-cresol, 16.0 g of anhydrous glycerol and 2.373 g of Na 2 HPO 4 , 2H 2 O. After mixing, pH was adjusted to 7.3 by means of IN NaOH. Addition of 10 ml of a solution containing 1% polyoxyethylene-23-laurylether (corresponding to a concentration of 100 ppm), was followed by topping with water to 1 litre, and the solution was sterile filtrated.
- Crystalline pork insulin corresponding to 100,000 IU containing 0.7% Zn was dissolved in 400 ml of water by means of 3,3 ml of IN HCl. Then were added 500 ml of a solution of 3.0 g of m-cresol, 16 g of anhydrous glycerol and 2.373 g of Na 2 HPO 4 , 2H 2 O. After mixing pH was adjusted to 7.3 by means of IN NaOH. Addition of 1 ml of a solution of 1% polyoxyethylene-15-tridecylether (corresponding to a concentration of 10 ppm)was followed by topping with water to 1 litre, and the solution was sterile filtrated.
- 1% polyoxyethylene-15-tridecylether corresponding to a concentration of 10 ppm
- Crystalline pork insulin (40,000 ID) having 0.6% by weight of zinc was dissolved in 200 ml ofwater with addition of 3 ml of IN hydrochlorid acid. This solution was admixed with 700 ml of a solution of 1 g of p- hydroxybenzoic acid methylester, 17 g of glycerol, 1.4 g of sodium acetate, 3 H 2 O and 10 mg of linear polypropylene glycol of an average molecular weight of 1.750. The solution was adjusted to a pH of 6.9 to 7.4. Water was topped up to 1-0 litre, and the solutionwas sterile filtrated. Shaking tests like in example 1 demonstrated that the stability only lasted for 200 hours.
Abstract
The insulin preparation, which is suitable for use in insulin delivery devices, consists of an insulin-containing aqueous medium having a pH of 6.5 to 9 and a polyoxyethylene alkylether of the general formula R - O - (CH2 - CH2 - O)n - H wherein R represents a straight or branched, saturated or unsaturated C8 - C15 alkyl group, and n is an integer from 2 to 25, and, if desired, common additives, such as isotonics, preservatives, buffers, etc., and optionally also a component causing the effect of the preparation to be accelerated or protracted. The preparation is prepared by admixing an aqueous medium containing human or animal insulin or a derivative thereof with a polyoxyethylene alkylether, and if necessary, adjusting the pH of the medium to 6.5 to 9, and if desired, adding any residual components of the medium and/or adjusting the insulin concentration to provide the finished preparation. After more than 500 hours' of constant shaking in the presence of atmospheric air in 3/4 filled vials, disposed horizontally, at 37<o>C with 80 oscillations per minute, such preparations arestill clear and without physical or chemical conversions.
Description
The present invention relates to a novel stable therapeutic insulin preparation in an aqueous medium suitable for use in insulin delivery devices, including portable devices for external as well as internal use.
It is generally held that most of the complications that may arise in connection with an insulin-dependent diabetes can be ascribed to inadequate control of the glucose content in the blood (Tehobroutsky, Diabetologia, 15, 143- 152 (1978)). In the conventional insulin therapy, insulin is administered to the diabetic by way of one to three inj.ections per day, resulting in a fluctuating insulin and glucose content in the blood. In contrast, the non- diabetic constantly receives insulin from his pancreas, secreted in the blood stream and in an amount adapted to his needs .
In recent years efforts have therefore been concentrated on the development of insulin delivery devices which can remedy the above-mentioned problem. If, however, such devices are applied internally or externally to a human, insulin preparations experience far inferior storage conditions in terms of temperature and motion when stored in the reservoir of the device than the injectable preparations. The previously known insulin preparations are intended for storage at rest at 4ºC. In contrast, the insulin preparation. is stored in the reservoir of insulin devices for an extended period of time at temperatures between 30 and 37ºC. and is moreover subjected to a good deal of motion during this period.
It is known that insulin in solution is adsorbed to hydro
phobic interfaces, including interfaces between aqueous solution and air (Weisenfeld et al., Diabetes 17, 766 (1968)). The insulin thus adsorbed can denature, and aggregation can also take place. Then, these aggregates of denatured insulin are desorbed from the interface, and they sediment and form a precipitate at a sufficiently high concentration in the solution. These processes are accelerated by increasing temperatures and motion.
Thus, it is not to be wondered at that it has turned out that in the use of the conventional dissolved insulin preparations in delivery devices, the supply tubes, valves and filters of the system are often gradually blocked by precipitated insulin aggregates, and that the desired very precise dosing of the insulin into the blood stream is prevented by this. These problems of aggregation have been discussed in great detail by W.D. Lougheed et al., Diabetologia 19, 1-9 (1980), reporting that the varying tendency to aggregation may be attributable to temperature, ion concentration and type, pH value, presence of carbon dioxide and other gases, as well as other factors.
It has been found for conventional insulin preparations that the quality of the insulin reaching the blood stream after an extended stay in a delivery device with associated reservoir is significantly inferior to the quality after storage and use under the common conditions.
This, too, is understandable because of the aggregation and/or formation of denatured insulin which takes place during the storage in the reservoir of the delivery device.
Thus, it is not possible with the combination of delivery device/conventional insulin preparation to solve the problem referred to.
It is proposed in the Danish Application 1851/80, cf. the EP 18609, relating to denaturation-resistant, aqueous protein solutions, including insulin solutions, to solve the problem by adding to the solution a surfactant having a chain-like basic structure, whose links contain alternating slightly hydrophobic and slightly hydrophilic regions, preferably a homopolymerisate, copolymerisate or block polymerisate of the formula
R2Y - Xn - R3 (I)
wherein X represents a chain of n links of the formulae (2) or (3)
Y represents oxygen or imino,
R1 represents hydrogen, methyl or ethyl, where the groups
R1 may be the same or different, with the proviso that methyl or ethyl is present in at least half of the chain links X, and R2 and R3 independently represent hydrogen or an organic group, preferably alkyl of 1 to 20 carbon atoms, carboxyalkyl of 2 to 20 carbon atoms or alkylphenyl of 1 to 10 alkyl carbon atoms, with the proviso that when Y represents imino R2 can only represent alkyl of 1 to 20 carbon atoms. These surfactants "saturate" the interfaces since the hydrophobic groups of the chains bind well to a larger hydrophobic face. However, the hydrophobic regions of the dissolved proteins only present very small faces to which the surfactants do not bind, and for the same reason the proteins cannot bind to the hydrophobic face as long as free' surface-active elements
are present in the solution. It is not denied that the protein solutions produced in examples 1-6 possess the properties described in that application, such as stability. But it is quite evident that in connection with insulin solutions the invention does not solve the problems associated with the insulin preparations to be used in delivery devices, and as described in the foregoing. It is noted that examples 7-13 (insulin) do not in fact report any stability, as is the case with examples 1-6. Reproduction of example 11 showed, as stated below, inadequate durability in shaking tests.
It has now surprisingly been found that a narrow group of non-ionic surfactants of the polyoxyethylene alkylether type in. extremely low concentrations effectively prevent the denaturations and aggregations that occur if insulin in an aqueous medium is subjected to elevated temperatures while being moved in the presence of air.
Accordingly, the invention relates to a stable aqueous, therapeutic insulin preparation which is particularly useful in insulin delivery devices and is unique in that the aqueous medium has a pH of 6.5 to 9 and contains a polyoxyethylene alkylether of the general formula
R - 0 - (CH2 - CH2 - 0)n - H (4)
wherein R represents a straight or branched, saturated or unsaturated C8 - C15 alkyl group, and n is an integer from 2 to 25.
Preferred compounds are in particular those of formula 4 wherein R represents a C12 - C13 alkyl group, preferably lauryl or tridecyl, because they give the best stability. n in the compounds of formula 4 is an integer, preferably from 4 to 23, in particular 6 to 15.
These polyoxyethylene alkylethers are active in insulin preparations in an aqueous medium in concentrations down to 2 ppm. The effect for concentrations between 2 and 100 ppm is demonstrated below, but the compounds are also active in higher concentrations, such as 100 to
300 ppm or more, e.g. up to 1000 ppm. The concentration most appropriate in the individual case can be determined by tests and depends e.g. upon the type of the compound, the concentration of insulin and the other components of the medium, as well as upon the mode of application of the preparation.
The above-mentioned compounds are comprised by the general formula for a group of non-ionic surfactants which prevent denaturation of insulin and adsorption to interfaces according to the DE Offenlegunσsschrift 29 17 53.5. The compounds used in accordance with the invention are not described in detail or examined in the examples of that specification/ which are included in the EP 18609 claiming priority from this DE application. In the EP 18609, the formula of the active compounds is restricted to formula 1 above. Compounds of the type used in accordance with the invention have directly been characterized as having no protective effect during the processing of the EP 18609 by the EPO in connection with a discussion of the DE Auslegeschrift 26 20 483.
This specification concerns stable aqueous insulin solutions, in particular for nasal administration. The solutions have a pH of 2.5 to 4.7 and contain one or more non-ionic surfactants having an HLB value of 9 to 22 and/or polyethylene glycol having a molecular weight of 200 to 7500 as a stabilizer to counteract the ceamidation of the insulin, well-known in the acid pH range, and to improve the shelf-life by counteracting gel formation and precipitations. The content of surfactant
usually constitutes 0.1 to 20% by weight, preferably 0.5 to 10% by weight. A content below 0.1% is characterized as being insufficient.
Examples of useful non-ionic compounds are stated to include a large number of types, such as compounds of polyoxyethylene and hydrogenated castor oil, polyoxyethylene fatty acid esters, polyoxyethylenesorbitan fatty acid esters, polyoxyethylenealkylphenyl ethers, polyoxyethylene-polyoxypropylene alkylethers and finally polyoxyethylene alkylethers of formula 4, in which, however, R may represent C 4 - C18 and n = 3 to 60.
Apart from the fact that the skilled person who realized the inadequate stabilizing effect by shaking tests with the. compounds used in the EP 18609 would not be induced at all to test compounds which are known as stabilizers against deamidation of insulin in acid solutions, he could in particular not predict that precisely the narrow range of compounds proposed by the present invention would be effective. This is the more surprising as the structurally closely related esters of the formula
R' - CO - O - (CH2 - CH2 - O)n - H (5)
wherein R' and n have values corresponding to formula 4, are inactive as stabilizers in shaking tests.
The Zn content in the medium can constitute 0 to 5%, preferably 0 to 1%, in particular 0.3 to 1% of the insulin, expressed as weight per cent of anhydrous insulin. However, a particularly good effect of the polyoxyethylene alkylethers is obtained when the Zn content in the dissolved insulin constitutes between 0.6 and 0.9%. The pH value is, as mentioned, between 6.5 and 9.0, but is preferably 6.5 to 8.0, in particular 7.0 to 8.0. The insulin concen
tration may be up to 1500 IU/ml.
According to the invention, aqueous insulin preparations for the use described can be prepared by the following general procedure:
Human or animal insulin or biologically active derivatives thereof are dissolved in water with addition of e.g. an HCl solution. The Zn content is adjusted by adding a solution of a Zn salt in water. The resulting solution is admixed with a solution that may contain a preservative, such as phenol, m-cresol or p-methylhydroxy benzoate; an isotonic, such as glucose, glycerol or sodium chloride, and - to maintain a specific pH - a buffer such as acetate or sodium phosphate. pH is adjusted to the desired value e.g. with an NaOH solution or an HCl solution. Finally, the stabilizing polyoxyethylene alkylether dissolved in water is added.
Optionally, the insulin may be dissolved directly in an aqueous medium containing a buffer, an isotonic, a preservative and the stabilizing compound, and then the Zn content and the pH are adjusted.
The order of these steps is arbitrary, it being possible to vary it in different ways; e.g. the stabilizing polymer might be added to the insulin during the purification process of the insulin.
Thus, the invention also relates to a process for preparing the present insulin preparations which comprises admixing an aqueous medium containing insulin with a polyoxyethylene alkylether of the formula
R - 0 - (CH2 - CH2 - O) n - H ( 4)
wherein R and n are as defined above, and, if necessary, adjusting the pH of the medium to 6.5 to 9, and, if desired, adding any residual components of the medium and/or adjusting the insulin concentration to provide the finished preparation.
The invention will be illustrated more fully by the following examples.
EXAMPLE 1
Crystalline pork insulin corresponding to 100,000 IU containing 0.4% Zn was dissolved in 400 ml of water by means of 3.3 ml of IN HCl. 10 ml of a ZnCl2 solution were added, containing 2.20 mg of ZnCl2 per ml. Then were added 500 ml of a solution of 3.0 g of m-cresol, 16.0 g of anhydrous glycerol and 2.373 g of Na2HPO4, 2H2O. After mixing, pH was adjusted to 7.3 by means of IN NaOH. Addition of 10 ml of a solution containing 1% polyoxyethylene-23-laurylether (corresponding to a concentration of 100 ppm), was followed by topping with water to 1 litre, and the solution was sterile filtrated.
After more than 699 hours' of constant shaking in the presence of atmospheric air in 3/4 filled vials, disposed horizontally, at 37ºC with 80 oscillations per minute, the preparation was still clear and without physical or chemical conversions.
EXAMPLE 2
The procedure was the same as in example 1, but with polyoxyethylene-10-laurylether substituted. for polyoxyethylene-23-laurylether.
A preparation of the same quality as in example 1 was obtained.
EXAMPLE 3
Crystalline pork insulin corresponding to 100,000 IU containing 0.7% Zn was dissolved in 400 ml of water by means of 3,3 ml of IN HCl. Then were added 500 ml of a solution of 3.0 g of m-cresol, 16 g of anhydrous glycerol and 2.373 g of Na2HPO4, 2H2O. After mixing pH was adjusted to 7.3 by means of IN NaOH. Addition of 1 ml of a solution of 1% polyoxyethylene-15-tridecylether (corresponding to a concentration of 10 ppm)was followed by topping with water to 1 litre, and the solution was sterile filtrated.
After more than 1000 hours' of constant shaking in the presence of atmospheric air in 3/4 filled vials, disposed horizontally, at 37°C with 80 oscillations per minute, the insulin preparation was still clear and without physical or chemical conversions.
EXAMPLE 4
The procedure was the same as in example 3, but using polyoxyethylene-6-tridecylether added to insulin solutions in concentrations corresponding to 2 ppm, 5 ppm, 10 ppm, 25 ppm, 50 ppm, and 100 ppm, respectively.
The solutions were subjected to shaking tests like in example 3, and all of them were clear and without physical or chemical conversions after more than 1000 hours' of shaking.
EXAMPLE 5 (Comparative example)
The procedure was the same as in example 1, adding, however, 100 ppm polyoxyethylene-20-cetylether (R = C16) instead of polyoxyethylene-23-laurylether.
Shaking tests like in example 1 demonstrated that the stability only lasted for 137 hours.
EXAMPLE 6 (Comparative example)
The procedure was the same as in example 1, adding, however, 100 ppm "Nopalcol L-4", which is a polyoxyethylene-9-laurate, instead of polyoxyethylene-23-laurylether. The solutionwas cloudy from the beginning and remained cloudy.
It will be seen from the foregoing examples that the closely related polyoxyalkylene alkylesters are inactive.
There is no fixed limit of satisfactory stabilizing effect in the above-mentioned shaking tests. The applicant has set 300 hours as a minimum, internal standard for pump insulin preparations with additives.
In view of this it is clear that polyoxyethylene alkylethers of formula 4 in which R is C16 are not satisfactory.
COMPARATIVE EXAMPLE 7 (reproduction of example 11 in the EP 18609)
Crystalline pork insulin (40,000 ID) having 0.6% by weight of zinc was dissolved in 200 ml ofwater with addition of 3 ml of IN hydrochlorid acid. This solution was admixed with 700 ml of a solution of 1 g of p- hydroxybenzoic acid methylester, 17 g of glycerol, 1.4 g of sodium acetate, 3 H2O and 10 mg of linear polypropylene glycol of an average molecular weight of 1.750. The solutionwas adjusted to a pH of 6.9 to 7.4. Water was topped up to 1-0 litre, and the solutionwas sterile filtrated.
Shaking tests like in example 1 demonstrated that the stability only lasted for 200 hours.
Claims
1. A stable aqueous, therapeutic insulin preparation suitable for use in insulin delivery devices, c h a r a c t e r i z e d in that the aqueous medium has a pH of 6.5 to 9 and contains a polyoxyethylene alkylether of the general formula
R - 0 - (CH2 - CH2 - 0)n - H (4)
wherein R represents a straight or branched, saturated or unsaturated C8 - C15 alkyl group, and n is an integer from 2 to 25.
2.. An insulin preparation according to claim 1, c h a r a c t e r i z e d in that it contains a compound of formula 4 wherein R represents a C12 - C13 alkyl group.
3. An insulin preparation according to claim 1 or 2, c h a r a c t e r i z e d in that it contains a compound of formula 4 wherein n is an integer from 4 to 23, in particular 6 to 15.
4. An insulin preparation according to claims 1-3, c h a r a c t e r i z e d in that the aqueous medium contains human or animal insulin or a derivative thereof and, if desired, common additives, such as isotonics, preservatives, buffers, etc., and optionally also a component causing the effect of the preparation to be accelerated or protracted.
5. An insulin preparation according to claims 1-4, c h a r a c t e r i z e d in that it contains human or animal insulin in a concentration of up to 1500 IU/ml.
6. An insulin preparation according to claims 1-5, c h a r a c t e r i z e d in that it contains at least 2 ppm of a compound of formula 4.
7. A process for preparing an insulin preparation according to claim 1, c h a r a c t e r i z e d by admixing an aqueous medium containing insulinwith a polyoxyethylene alkylether of the formula
R - 0 - (CH2 - CH2 - 0)n - H (4)
wherein R and n are as defined in claim 1, and, if necessary, adjusting the pH of the medium to 6.5 to 9, and, if desired, adding any residual components of the medium and/or adjusting the insulin concentration to provide the finished preparation.
8. A process according to claim 7, c h a r a c t e r i z e d by adding a compound of formula 4 wherein R represents a C12 - C13 alkyl group.
9. A process according to claim 7 or 8, c h a r a c t e ri z e d by adding a compound of formula 4 wherein n is
4 to 23, in particular 6 to 15.
10. A process according to claims 7-9, c h a r a c t e ri z e d by adding at least 2 ppm of a compound of formula 4.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK096483A DK152409C (en) | 1981-07-17 | 1983-02-28 | PROCEDURE FOR THE PREPARATION OF A STABLE Aqueous Therapeutic Insulin Preparation |
FI830871A FI830871A0 (en) | 1981-07-17 | 1983-03-16 | ETT STABILT VATTENHALTIGT TERAPEUTISKT INSULIN PREPARAT OCH ETT FOERFARANDE FOER FRAMSTAELLNING DAER |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK319881 | 1981-07-17 | ||
DK3198/81810717 | 1981-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1983000288A1 true WO1983000288A1 (en) | 1983-02-03 |
Family
ID=8120177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1982/000068 WO1983000288A1 (en) | 1981-07-17 | 1982-07-16 | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0083619A1 (en) |
JP (1) | JPS58501125A (en) |
AU (1) | AU558474B2 (en) |
NO (1) | NO830933L (en) |
WO (1) | WO1983000288A1 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0098110A2 (en) * | 1982-06-24 | 1984-01-11 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
EP0131864A2 (en) * | 1983-07-13 | 1985-01-23 | Hoechst Aktiengesellschaft | Denaturation-resistant aqueous solutions of proteins, process for preparing them and their use |
DE3443877A1 (en) * | 1984-06-09 | 1985-12-12 | Hoechst Ag | Insulin preparations, process for their preparation, and their use |
DE3716437A1 (en) * | 1986-05-27 | 1987-12-03 | Sandoz Ag | PHARMACEUTICAL COMPOSITION |
US5902789A (en) * | 1986-04-23 | 1999-05-11 | Fisons Corporation | Nasal administration of drugs |
US6221633B1 (en) | 1997-06-20 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Insulin derivatives having a rapid onset of action |
AU753673B2 (en) * | 1997-08-04 | 2002-10-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
AU2002300833B2 (en) * | 1997-08-04 | 2007-05-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
US7476652B2 (en) | 2002-06-18 | 2009-01-13 | Sanofi-Aventis Deutschland Gmbh | Acidic insulin preparations having improved stability |
US7696162B2 (en) | 2001-03-23 | 2010-04-13 | Sanofi-Aventis Deutschland Gmbh | Zinc-free and low-zinc insulin preparations having improved stability |
RU2506945C2 (en) * | 2009-03-03 | 2014-02-20 | Байодел Инк. | Rapidly fixed dosage forms of insulin |
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US10092513B2 (en) | 2013-04-03 | 2018-10-09 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2620483A1 (en) * | 1975-06-13 | 1976-12-23 | Takeda Chemical Industries Ltd | STABLE AQUATIC INSULIN SOLUTIONS |
DE2620446A1 (en) * | 1975-08-20 | 1977-03-03 | Takeda Chemical Industries Ltd | Aqueous INSULIN PREPARATION |
DE2641819A1 (en) * | 1975-09-26 | 1977-04-07 | Yamanouchi Pharma Co Ltd | PHARMACEUTICAL PREPARATION OF INSULIN FOR RECTAL USE |
US4164573A (en) * | 1975-06-13 | 1979-08-14 | Galinsky Alvin M | Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal |
DE2917535A1 (en) * | 1979-04-30 | 1980-11-06 | Hoechst Ag | Stabilised aq. insulin solns. - contg. polyethylene, polypropylene or polybutylene glycol surfactant to stabilise against denaturation by hydrophobic surfaces or air |
-
1982
- 1982-07-16 JP JP57502198A patent/JPS58501125A/en active Pending
- 1982-07-16 WO PCT/DK1982/000068 patent/WO1983000288A1/en not_active Application Discontinuation
- 1982-07-16 AU AU87304/82A patent/AU558474B2/en not_active Ceased
- 1982-07-16 EP EP82902164A patent/EP0083619A1/en not_active Withdrawn
-
1983
- 1983-03-16 NO NO830933A patent/NO830933L/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2620483A1 (en) * | 1975-06-13 | 1976-12-23 | Takeda Chemical Industries Ltd | STABLE AQUATIC INSULIN SOLUTIONS |
US4164573A (en) * | 1975-06-13 | 1979-08-14 | Galinsky Alvin M | Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal |
DE2620446A1 (en) * | 1975-08-20 | 1977-03-03 | Takeda Chemical Industries Ltd | Aqueous INSULIN PREPARATION |
DE2641819A1 (en) * | 1975-09-26 | 1977-04-07 | Yamanouchi Pharma Co Ltd | PHARMACEUTICAL PREPARATION OF INSULIN FOR RECTAL USE |
DE2917535A1 (en) * | 1979-04-30 | 1980-11-06 | Hoechst Ag | Stabilised aq. insulin solns. - contg. polyethylene, polypropylene or polybutylene glycol surfactant to stabilise against denaturation by hydrophobic surfaces or air |
Non-Patent Citations (5)
Title |
---|
Chemical Abstracts, Vol 86 (1977), abstract No 177336r, Japan. Kokai 77 25,013 * |
International Journal of Pharmaceutics, Vol 9, No 2, issued August 1981 (Elsevier/North-Holland Biomedical Press, Amsterdam), S Hirai et al, "Effect of surfactants on the nasal absorption of insulin in rats", see pages 165-172, especially page 168 and page 165, lines 8-4 from the bottom. * |
International Journal of Pharmaceutics, Vol 9, No 2, issued August 1981 (Elsevier/North-Holland Biomedical Press, Amsterdam), S Hirai et al, "Mechanisms for the enhancement of the nasal absorption of insulin by surfactants", see pages 173-184, especially pages 178-179 and 173, lines 9-5 from the bottom. * |
Journal of Pharmacy and Pharmacology, Vol 32, issued 1980 (London), K Ichikawa et al, "Rectal absorption of insulin suppositories in rabbits", see pages 314-318. * |
Journal of Pharmacy and Pharmacology, Vol 33, No 11, issued November 1981 (London), M S Mesiha & H I EL-Bitar, "Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 and stearic acid", see pages 733-734. * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0098110A3 (en) * | 1982-06-24 | 1986-03-05 | Nihon Chemical Research Kabushiki Kaisha Also Known As Japan Chemical Research Co., Ltd | Long-acting composition |
EP0098110A2 (en) * | 1982-06-24 | 1984-01-11 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
EP0131864A2 (en) * | 1983-07-13 | 1985-01-23 | Hoechst Aktiengesellschaft | Denaturation-resistant aqueous solutions of proteins, process for preparing them and their use |
EP0131864A3 (en) * | 1983-07-13 | 1987-08-26 | Hoechst Aktiengesellschaft | Denaturation-resistant aqueous solutions of proteins, process for preparing them and their use |
DE3443877A1 (en) * | 1984-06-09 | 1985-12-12 | Hoechst Ag | Insulin preparations, process for their preparation, and their use |
US5902789A (en) * | 1986-04-23 | 1999-05-11 | Fisons Corporation | Nasal administration of drugs |
WO1987007149A1 (en) * | 1986-05-27 | 1987-12-03 | Sandoz Ag | Pharmaceutical compositions |
FR2599254A1 (en) * | 1986-05-27 | 1987-12-04 | Sandoz Sa | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDES ADAPTED TO GASTROINTESTINAL RESORPTION. |
BE1000722A4 (en) * | 1986-05-27 | 1989-03-21 | Sandoz Sa | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDES ADAPTED TO GASTROINTESTINAL RESORPTION. |
GB2190838B (en) * | 1986-05-27 | 1990-12-12 | Sandoz Ltd | Pharmaceutical compositions |
DE3716437A1 (en) * | 1986-05-27 | 1987-12-03 | Sandoz Ag | PHARMACEUTICAL COMPOSITION |
US6221633B1 (en) | 1997-06-20 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Insulin derivatives having a rapid onset of action |
AU753673B2 (en) * | 1997-08-04 | 2002-10-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
AU2002300833B2 (en) * | 1997-08-04 | 2007-05-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
US7696162B2 (en) | 2001-03-23 | 2010-04-13 | Sanofi-Aventis Deutschland Gmbh | Zinc-free and low-zinc insulin preparations having improved stability |
US7713930B2 (en) | 2002-06-18 | 2010-05-11 | Sanofi-Aventis Deutschland Gmbh | Acidic insulin preparations having improved stability |
US7476652B2 (en) | 2002-06-18 | 2009-01-13 | Sanofi-Aventis Deutschland Gmbh | Acidic insulin preparations having improved stability |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
US10117909B2 (en) | 2008-10-17 | 2018-11-06 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1 agonist |
RU2506945C2 (en) * | 2009-03-03 | 2014-02-20 | Байодел Инк. | Rapidly fixed dosage forms of insulin |
US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US10028910B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
US9987332B2 (en) | 2011-09-01 | 2018-06-05 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US10220163B2 (en) | 2012-04-13 | 2019-03-05 | Boehringer Ingelheim International Gmbh | Nebuliser with coding means |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US11191722B2 (en) | 2013-04-03 | 2021-12-07 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US10092513B2 (en) | 2013-04-03 | 2018-10-09 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10894134B2 (en) | 2013-08-09 | 2021-01-19 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US11642476B2 (en) | 2013-08-09 | 2023-05-09 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10716905B2 (en) | 2014-02-23 | 2020-07-21 | Boehringer Lngelheim International Gmbh | Container, nebulizer and use |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
Also Published As
Publication number | Publication date |
---|---|
NO830933L (en) | 1983-03-16 |
AU8730482A (en) | 1983-03-17 |
JPS58501125A (en) | 1983-07-14 |
EP0083619A1 (en) | 1983-07-20 |
AU558474B2 (en) | 1987-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1983000288A1 (en) | A stable aqueous, therapeutic insulin preparation and a process for preparing it | |
US4839341A (en) | Stabilized insulin formulations | |
US6548079B1 (en) | Moxifloxacin formulation containing common salt | |
AT402259B (en) | Process for the production of a stable pharmaceutical product with a content of granulocyte colony stimulating factor | |
EP0921812B2 (en) | Insulin preparations containing a halogenide | |
AU695937B2 (en) | Intraocular irrigating solution containing agent for controlling IOP | |
EP0166529B1 (en) | Stabilized insulin formulation | |
JP2002500196A (en) | Stabilized insulin composition | |
KR101253941B1 (en) | Transparent eye drops containing latanoprost | |
EP0824916B1 (en) | Pranoprofen eyedrops containing organic amine | |
CA2246501A1 (en) | Stabilised growth hormone formulation and method of preparation thereof | |
EP2193795A1 (en) | Latanoprost-containing aqueous pharmaceutical composition | |
JP2916340B2 (en) | Aqueous pharmaceutical composition of sodium cromoglycate | |
EP2243477A1 (en) | Paracetamol for parenteral application | |
JP2001261578A (en) | Ophthalmic composition | |
JPH06247853A (en) | Stable eye drop having solubilized vitamin as and vitamin es | |
GB2072015A (en) | Compositions containing polymyxin | |
JPH075456B2 (en) | Eye drops | |
US4289783A (en) | Etomidate-containing compositions | |
EP0048944A1 (en) | An antimicrobial preparation | |
JP2530491B2 (en) | Hyaluronic acid eye drops | |
CN102215819B (en) | Pharmaceutical composition having relatively low ionic strength | |
JP4610154B2 (en) | Injectable preparation | |
DK152409B (en) | PROCEDURE FOR THE PREPARATION OF A STABLE Aqueous Therapeutic Insulin Preparation | |
EP0375885A1 (en) | Aqueous elcatonin solution composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU DK FI JP NO US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1982902164 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 830871 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1982902164 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1982902164 Country of ref document: EP |